Long Term Monitoring of Nutritional, Clinical Status and Quality of Life in Head and Neck Cancer Patients
Authors:
E. Malá 1; E. Vejražková 2; J. Bielmeierová 3; M. Jindra 3; M. Vošmik 4; J. Novosad 1; L. Sobotka 5
Authors‘ workplace:
Ústav klinické imunologie a alergologie, LF UK a FN Hradec Králové
1; IV. interní klinika LF UK a FN Hradec Králové
2; Rehabilitační klinika LF UK a FN Hradec Králové
3; Klinika onkologie a radioterapie LF UK a FN Hradec Králové
4; III. interní gerontometabolická klinika LF UK a FN Hradec Králové
5
Published in:
Klin Onkol 2015; 28(3): 200-214
Category:
Original Articles
doi:
https://doi.org/10.14735/amko2015200
Overview
Background:
Malnutrition in head and neck cancer (HNC) patients decreases survival, quality of life (QOL) and oncological outcomes. The aim of the prospective three-year study was to compare QOL, clinical symptoms and variables (complications, survival and mortality rates in HNC patients).
Patients and Methods:
A total of 726 patients aged 55 to 72 years with treatable HNC were included from January 2004 to December 2009; these patients were randomized to either group with PEG and enteral nutrition and nonPEG group with nutritional counselling according to nutritional care. We used EORTC questionnaires QOL C-30 and Head and neck module (HN-35) for measuring of QOL. The following variables due to expectable influence on QOL (demographic data, oncological data, nutritional screening, Clinical symptom score, Karnofsky performance status score, Charlson comorbidity index) were included. Monitoring was done five times in three years.
Results:
In the first six months, we found decrease of weight and body mass index (BMI). After this critical time point and finish of oncological treatment, a marked difference in the development of patients treated with PEG. Negative factors influencing patients survival, QOL, clinical status were males aged > 63 years, hypopharyngeal cancer (stage III– IV), smoking, weight loss > 10%, BMI < 21 and disallowance of PEG.
Conclusions:
QOL is an essential factor for cancer patients. Our study showed that nutritional intervention with early enteral nutrition may improve QOL and survival in HNC patients. The PEG group better tolerated oncological treatment, had lower incidence of complications, shorter time to re-entry of permanent increase in weight, lower rate of rehospitalization and its shorter length. We found QOL questionnaires to be very important for better understanding and communication and a key instrument for improving solution of patient’s difficulties during their therapy in multidisciplinary approach.
Key words:
head and neck cancer – quality of life – EORTC – C-30 – HN-35 – PEG – malnutrition
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.
Submitted:
16. 4. 2015
Accepted:
4. 5. 2015
Sources
1. Zvolsky M, Nechanska B, Kralikova E. The use of diagnoses related to tobacco use in the Czech Republic. Cas Lek Cesk 2012; 151(12): 573– 578.
2. Dusek L, Muzik J, Gelnarova E et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2010; 23(5): 311– 324.
3. Dusek L, Muzik J, Maluskova D et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2014; 27(6): 406– 423. doi: 10.14735/ amko2014406.
4. Chroust K, Finek J, Zemanek P et al. Experience in data management of the clinical retrospective project in Czech and Slovak oncology centres (IKARUS Project). Klin Onkol 2009; 22(4): 163– 167.
5. Elia M, Stratton R. On the ESPEN guidelines for nutritional screening 2002. Clin Nutr 2004; 23(1): 131– 132.
6. Fearon KC. The 2011 ESPEN Arvid Wretlind lecture: cancer cachexia: the potential impact of translational research on patient-focused outcomes. Clin Nutr 2012; 31: 577– 582. doi: 10.1016/ j.clnu.2012.06.012.
7. Kondrup J, Allison SP, Elia M et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003; 22(4): 415– 421.
8. Lochs H, Allison SP, Meier R et al. Introductory to the ESPEN Guidelines on Enteral Nutrition: terminology, definitions and general topics. Clin Nutr 2006; 25(2): 180– 186.
9. Meier R. Enteral feeding in tumor patients. Schweiz Med Wochenschr 1995; 125(5): 159– 162.
10. Sobotka L, Schneider SM, Berner YN et al. ESPEN Guidelines on Parenteral Nutrition: geriatrics. Clin Nutr 2009; 28(4): 461– 466. doi: 10.1016/ j.clnu.2009.04.004.
11. Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12(5): 489– 495. doi: 10.1016/ S1470-2045(10)70218-7.
12. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10(2): 90– 99. doi: 10.1038/ nrclinonc.2012.209.
13. Fearon KC, Borland W, Preston T et al. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr 1988; 47(1): 42– 48.
14. Jager-Wittenaar H, Dijkstra PU, Vissink A et al. Changes in nutritional status and dietary intake during and after head and neck cancer treatment. Head Neck 2011; 33(6): 863– 870. doi: 10.1002/ hed.21546.
15. Dahlman I, Mejhert N, Linder K et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br J Cancer 2010; 102(10): 1541– 1548. doi: 10.1038/ sj.bjc.6605665.
16. Dhanapal R, Saraswathi T, Govind RN. Cancer cachexia. J Oral Maxillofac Pathol 2011; 15(3): 257– 260. doi: 10.4103/ 0973-029X.86670.
17. Groarke JD, Cheng S, Jones LW et al. Cancer cachexia: getting to the heart of the matter. Eur Heart J 2013; 32(4): 121–123.
18. Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care 2014; 8(4): 321– 327. doi: 10.1097/ SPC.0000000000000091.
19. Wang H, Ye J. Regulation of energy balance by inflammation: common theme in physiology and pathology. Rev Endocr Metab Disord 2015; 16(1): 47– 54. doi: 10.1007/ s11154-014-9306-8.
20. Malik ST. Tumour necrosis factor: roles in cancer pathophysiology. Semin Cancer Biol 1992; 3(1): 27– 33.
21. Laviano A, Seelaender M, Rianda S et al. Neuroinflammation: a contributing factor to the pathogenesis of cancer cachexia. Crit Rev Oncog 2012; 17(3): 247– 251.
22. Thair S, Russell JA. Noncanonical nuclear factor kappa B (NF-kappaB) signaling and potential for therapeutics in sepsis. Curr Infect Dis Rep 2013; 15(5): 364– 371. doi: 10.1007/ s11908-013-0362-0.
23. Thair SA, Walley KR, Nakada TA et al. A single nucleotide polymorphism in NF-kappaB inducing kinase is associated with mortality in septic shock. J Immunol 2011; 186(4): 2321– 2328. doi: 10.4049/ jimmunol.1002864.
24. Thair SA, Russell JA. Sepsis in transit: from clinical to molecular classification. Crit Care 2012; 16(6): 173. doi: 10.1186/ cc11813.
25. Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol 2003; 1(3): 159– 168.
26. Tisdale MJ. The cancer cachectic factor‘. Support Care Cancer 2003; 11(2): 73– 78.
27. Tisdale MJ. Cancer cachexia. Langenbecks Arch Surg 2004; 389(4): 299– 305.
28. Mantovani G, Maccio A, Madeddu C et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med (Berl) 2001; 79(7): 406– 414.
29. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12(3): 223– 226. doi: 10.1097/ MCO.0b013e32832a7902.
30. Tisdale MJ. Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 2005; 20: 340– 348.
31. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992; 11(4): 445– 456.
32. Maddocks M, Jones LW, Wilcock A. Immunological and hormonal effects of exercise: implications for cancer cachexia. Curr Opin Support Palliat Care 2013; 7(4): 376– 382. doi: 10.1097/ SPC.0000000000000010.
33. Briddon S, Beck SA, Tisdale MJ. Changes in activity of lipoprotein lipase, plasma free fatty acids and triglycerides with weight loss in a cachexia model. Cancer Lett 1991; 57(1): 49– 53.
34. Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 2013; 4(2): 95– 109. doi: 10.1007/ s13539-012-0087-1.
35. Takahashi M, Terashima M, Takagane A et al. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int J Clin Oncol 2009; 14(4): 315– 320. doi: 10.1007/ s10147-008-0856-1.
36. Bossola M. Nutritional interventions in head and neck cancer patients undergoing chemoradiotherapy: a narrative review. Nutrients 2015; 7(1): 265– 276. doi: 10.3390/ nu7010265.
37. Bozzetti F. Nutritional support of the oncology patient. Crit Rev Oncol Hematol 2013; 87(2): 172– 200. doi: 10.1016/ j.critrevonc.2013.03.006.
38. Cacicedo J, Casquero F, Martinez-Indart L et al. A prospective analysis of factors that influence weight loss in patients undergoing radiotherapy. Chin J Cancer 2014; 33(4): 204– 210. doi: 10.5732/ cjc.013.10009.
39. Giacosa A, Frascio F, Sukkar SG et al. Food intake and body composition in cancer cachexia. Nutrition 1996; 12 (Suppl 1): S20– S23.
40. Khatami M. Unresolved inflammation: ‚immune tsunami‘ or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer. Expert Opin Biol Ther 2011; 11(11): 1419– 1432. doi: 10.1517/ 14712598.2011.592826.
41. Martin L, Birdsell L, Macdonald N et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31(12): 1539– 1547. doi: 10.1200/ JCO.2012.45.2722.
42. Vassilopoulos PP, Filopoulos E, Kelessis N et al. Competent gastrostomy for patients with head and neck cancer. Support Care Cancer 1998; 6(5): 479– 481.
43. van Bokhorst-De van der Schuer MA, von Blomberg-van der Flier BM, Riezebos RK et al. Differences in immune status between well-nourished and malnourished head and neck cancer patients. Clin Nutr 1998; 17(3): 107– 111.
44. Takenaka Y, Takemoto N, Nakahara S et al. Prognostic significance of body mass index before treatment for head and neck cancer. Head Neck 2014. doi: 10.1002/ hed.23785.
45. Arends J, Bodoky G, Bozzetti F et al. ESPEN Guidelines on enteral nutrition: non-surgical oncology. Clin Nutr 2006; 25(2): 245– 259.
46. Loser C, Aschl G, Hebuterne X et al. ESPEN guidelines on artificial enteral nutrition – percutaneous endoscopic gastrostomy (PEG). Clin Nutr 2005; 24(5): 848– 861.
47. Lee JH, Machtay M, Unger LD et al. Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124(8): 871– 875.
48. Nicholl MB, Lyons DA, Wheeler AA et al. Repeat PEG placement is safe for head and neck cancer patients. Am J Otolaryngol 2014; 35(2): 89– 92. doi: 10.1016/ j.amjoto.2013.12.001.
49. Raykher A, Correa L, Russo L et al. The role of pretreatment percutaneous endoscopic gastrostomy in facilitating therapy of head and neck cancer and optimizing the body mass index of the obese patient. JPEN J Parenter Enteral Nutr 2009; 33(4): 404– 410. doi: 10.1177/ 0148607108327525.
50. Reilly JJ. Does nutrition management benefit the head and neck cancer patient? Oncology (Williston Park) 1990; 4(6): 105– 115.
51. Schutz T, Valentini L, Herbst B et al. ESPEN guidelines on enteral nutrition – summary. Z Gastroenterol 2006; 44(8): 683– 684.
52. Schutz T, Herbst B, Koller M. Methodology for the development of the ESPEN Guidelines on Enteral Nutrition. Clin Nutr 2006; 25(2): 203– 209.
53. Pai PC, Chuang CC, Tseng CK et al. Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. Int J Radiat Oncol Biol Phys 2012; 83(1): e93– e100. doi: 10.1016/ j.ijrobp.2011.11.071.
54. Ravasco P, Monteiro-Grillo I, Marques VP et al. Quality of life in gastrointestinal cancer: what is the impact of nutrition? Acta Med Port 2006; 19(3): 189– 196.
55. van Bokhorst-de van der Schuer, van Leeuwen PA, Kuik DJ et al. The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. Cancer 1999; 86(3): 519– 527.
56. Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47(11): 1245– 1251.
57. Charlson M, Wells MT, Ullman R et al. The Charlson comorbidity index can be used prospectively to identify patients who will incur high future costs. PLoS One 2014; 9(12): e112479. doi: 10.1371/ journal.pone.0112479.
58. Karnofsky DA, Ellison RR, Golbey RB. Selection of patients for evaluation of chemotherapeutic procedures in advanced cancer. J Chronic Dis 1962; 15: 243– 249.
59. Orell-Kotikangas H, Osterlund P, Saarilahti K et al. NRS-2002 for pre-treatment nutritional risk screening and nutritional status assessment in head and neck cancer patients. Support Care Cancer 2015; 23(6): 1495– 1502. doi: 10.1007/ s00520-014-2500-0.
60. Bozzetti F. Nutritional support in oncologic patients: where we are and where we are going. Clin Nutr 2011; 30(6): 714– 717. doi: 10.1016/ j.clnu.2011.06.011.
61. Iro H, Fietkau R, Kolb S et al. Nutrition of ENT tumor patients treated with radiotherapy. Comparison of oral and enteral nutrition using percutaneous gastrostomy. HNO 1989; 37(8): 343– 348.
62. Iwasaki T, Ohyanagi H. Advance and perspective of clinical nutrition. Nihon Geka Gakkai Zasshi 2004; 105(2): 196– 199.
63. Carmack CL, Basen-Engquist K, Gritz ER. Survivors at higher risk for adverse late outcomes due to psychosocial and behavioral risk factors. Cancer Epidemiol Biomarkers Prev 2011; 20(10): 2068– 2077. doi: 10.1158/ 1055-9965.EPI-11-0627.
64. Silander E, Nyman J, Bove M et al. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck 2012; 34(1): 1– 9. doi: 10.1002/ hed.21700.
65. So WK, Chan RJ, Chan DN et al. Quality-of-life among head and neck cancer survivors at one year after treatment – a systematic review. Eur J Cancer 2012; 48(15): 2391– 2408. doi: 10.1016/ j.ejca.2012.04.005.
66. Nelke KH, Pawlak W, Gerber H et al. Head and neck cancer patients‘ quality of life. Adv Clin Exp Med 2014; 23(6): 1019– 1027. doi: 10.17219/ acem/ 37361.
67. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5): 365– 376.
68. Bozzetti F. Quality of life and enteral nutrition. Curr Opin Clin Nutr Metab Care 2008; 11(5): 661– 665. doi: 10.1097/ MCO.0b013e32830a7099.
69. Petruson KM, Silander EM, Hammerlid EB. Quality of life as predictor of weight loss in patients with head and neck cancer. Head Neck 2005; 27(4): 302– 310.
70. Sat-Munoz D, Moran MA, Solano-Murillo P et al. EORTC QLQ-C30 questionnaire role as predictor for malnutrition risk in head and neck cancer Mexican patients. Nutr Hosp 2012; 27(2): 477– 482. doi: 10.1590/ S0212-16112012000200019.
71. Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer 1991; 67 (Suppl 3):844– 850.
72. Aaronson NK, Snyder C. Using patient-reported outcomes in clinical practice: proceedings of an International Society of Quality of Life Research conference. Qual Life Res 2008; 17(10): 1295. doi: 10.1007/ s11136-008-9422-6.
73. Bjordal K, Hammerlid E, Ahlner-Elmqvist M et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999; 17(3): 1008– 1019.
74. Laviano A, Renvyle T, Yang ZJ. From laboratory to bedside: new strategies in the treatment of malnutrition in cancer patients. Nutrition 1996; 12(2): 112– 122.
75. Onesti JK, Guttridge DC. Inflammation based regulation of cancer cachexia. Biomed Res Int 2014; 2014: 168407. doi: 10.1155/ 2014/ 168407.
76. Unal D, Orhan O, Eroglu C et al. Prealbumin is a more sensitive marker than albumin to assess the nutritional status in patients undergoing radiotherapy for head and neck cancer. Contemp Oncol (Pozn) 2013; 17(3): 276– 280. doi: 10.5114/ wo.2013.35281.
77. Senior K. Why is progress in treatment of cancer cachexia so slow? Lancet Oncol 2007; 8(8): 671– 672.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2015 Issue 3
Most read in this issue
- New Findings in Methotrexate Pharmacology – Diagnostic Possibilities and Impact on Clinical Care
- Podávání kontinuálních infuzí cytostatik pomocí elastomerických infuzorů
- Tumour Hypoxia – Molecular Mechanisms and Clinical Relevance
- Early Integration of Palliative Care into Standard Oncology Care – Benefits, Limitations, Barriers and Types of Palliative Care